Arca
Skip to content
Tools
Tools

PCSK9 mRNA

Nucleic acid in Homo sapiens that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Other 2

Approved1

  • Inclisiran sodium

Phase 31

  • Inclisiran

Phase 20

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      Inclisiran sodiumApprovedNovartis PharmaceuticalsOligonucleotideRnai inhibitorPCSK9 mRNA rnai inhibitor20
      InclisiranPhase 3Novartis PharmaceuticalsOligonucleotideRnai inhibitorPCSK9 mRNA RNAi inhibitor41

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 13 in all, from ClinicalTrials.gov.
      Lipid Management Gaps in Mexican Patients at High and Very High Cardiovascular RiskInclisiran—Not yet recruitingInstituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranNov 12, 2026
      Comparing Inclisiran Versus Statin for Primary AldosteronismInclisiranNot applicableRecruitingThird Military Medical UniversityOct 21, 2026
      Phase 2 Clinical Study of MWX203 Injection Alone or in Combination With Inclisiran Sodium Injection in Patients With Mixed DyslipidemiaInclisiran, Inclisiran sodiumPhase 2RecruitingShanghai Minwei Biotechnology Co., LtdSep 4, 2026
      Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary SyndromeInclisiran, Inclisiran sodiumPhase 4Not yet recruitingSeoul National University Bundang HospitalSep 2, 2026
      Aggressive Lipid Lowering Therapy in ICI-Treated MelanomaInclisiranNot applicableRecruitingUniversity of Colorado, DenverJul 15, 2026
      Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi ArabiaInclisiran, Inclisiran sodiumPhase 4Not yet recruitingNovartis PharmaceuticalsJul 6, 2026
      Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed FormulationInclisiranPhase 1RecruitingNovartis PharmaceuticalsJun 4, 2026
      A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant HypercholesterolemiaInclisiranPhase 2RecruitingNovartis PharmaceuticalsMay 27, 2026
      Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary SyndromesInclisiran sodiumPhase 3Active, not recruitingNovartis PharmaceuticalsAug 4, 2025
      Inclisiran Effectiveness in China: a Pragmatic Randomized TrialInclisiran sodiumPhase 4Active, not recruitingNovartis PharmaceuticalsApr 24, 2025
      Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular InterventionInclisiran sodiumPhase 4RecruitingDuke UniversityApr 3, 2025
      LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL LoweringInclisiran sodiumPhase 4RecruitingUniversity of California, San DiegoMar 10, 2025
      PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS)Inclisiran sodiumNot applicableNot yet recruitingWest China HospitalJan 24, 2025

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4630662, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.